

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this document (including any paper referred to as being attached or enclosed) is being sent to the U.S. Patent and Trademark Office via facsimile transmission to (703) 308-7924 on the date indicated below, with a coversheet addressed to Assistant Commissioner for Patents, U.S. Patent and Trademark Office, Washington, D.C., 20231.

Date: November 27, 2000
By: Willem F. Gadiano
Willem F. Gadiano, Registration No. 37,136

#10/A
AKO
1-6-01

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

J. Peter KLEIN et al.

Art Unit: 1614

Examiner: Criares, T

Serial No.: 09/288,556

Docket No.: 44033-080

Filed: April 9, 1999

For: THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING
AND METHODS FOR USING SAMEAMENDMENTHonorable Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

In response to the Office Action mailed May 26, 2000, please amend the above-captioned patent application, as follows:

IN THE CLAIMS

Claim 1, line 17, delete "secondary".

REMARKS

Claims 1-20 are pending. Claims 2-20 are withdrawn from consideration. Claim 1 is amended to clarify the subject matter sought to be patented. No new matter is added.

The Office Action rejects the elected species of claim 1 (i.e., compounds of Formula I wherein "x" and "y" are N and "z" is C) under 35 U.S.C. § 103(a) as being obvious over Novick, Jr. (5,039,666). Applicants respectfully traverse this rejection.